iSpecimen (ISPC) Stock Overview
Operates marketplace that provides biospecimens to life science researchers worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Risk Analysis
ISPC passed our risk checks.
ISPC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
iSpecimen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.74 |
| 52 Week High | US$8.30 |
| 52 Week Low | US$0.64 |
| Beta | 1.81 |
| 1 Month Change | -53.70% |
| 3 Month Change | -31.09% |
| 1 Year Change | -83.75% |
| 3 Year Change | -97.70% |
| 5 Year Change | n/a |
| Change since IPO | -99.48% |
Recent News & Updates
Recent updates
Benign Growth For iSpecimen Inc. (NASDAQ:ISPC) Underpins Stock's 26% Plummet
Mar 05
iSpecimen Inc. (NASDAQ:ISPC) Looks Inexpensive After Falling 38% But Perhaps Not Attractive Enough
Jan 01iSpecimen Inc. (NASDAQ:ISPC) Might Not Be As Mispriced As It Looks After Plunging 32%
Sep 13US$3.00: That's What Analysts Think iSpecimen Inc. (NASDAQ:ISPC) Is Worth After Its Latest Results
Aug 09Take Care Before Diving Into The Deep End On iSpecimen Inc. (NASDAQ:ISPC)
Jan 04Downgrade: Here's How This Analyst Sees iSpecimen Inc. (NASDAQ:ISPC) Performing In The Near Term
Aug 07Investors Still Aren't Entirely Convinced By iSpecimen Inc.'s (NASDAQ:ISPC) Revenues Despite 33% Price Jump
Apr 18iSpecimen names finance chief Tracy Curley as interim CEO
Sep 22iSpecimen Inc. (NASDAQ:ISPC) Analysts Just Slashed This Year's Estimates
Aug 10iSpecimen GAAP EPS of -$0.30 misses by $0.02, revenue of $2.3M misses by $0.55M
Aug 04iSpecimen Inc.'s (NASDAQ:ISPC) Intrinsic Value Is Potentially 69% Above Its Share Price
Mar 31Shareholder Returns
| ISPC | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | -14.7% | -2.8% | -1.5% |
| 1Y | -83.8% | 20.9% | 14.4% |
Price Volatility
| ISPC volatility | |
|---|---|
| ISPC Average Weekly Movement | 51.9% |
| Healthcare Services Industry Average Movement | 9.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.0% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 24 | Robert Lim | ispecimen.com |
iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers worldwide. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. Its marketplace offers human biospecimens, including Biofluids, such as whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid; Solid tissue comprising fresh, fixed, and cryopreserved tissue, as well as formalin-fixed paraffin embedded blocks, slides, and curls; and Hematopoietic stem and immune cells, including bone marrow, cord blood, whole blood, or sub-components of these tissues, such as peripheral blood mononuclear cells and other isolated cell types.
iSpecimen Inc. Fundamentals Summary
| ISPC fundamental statistics | |
|---|---|
| Market cap | US$4.48m |
| Earnings (TTM) | -US$10.19m |
| Revenue (TTM) | US$5.91m |
Is ISPC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ISPC income statement (TTM) | |
|---|---|
| Revenue | US$5.91m |
| Cost of Revenue | US$3.98m |
| Gross Profit | US$1.93m |
| Other Expenses | US$12.12m |
| Earnings | -US$10.19m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.84 |
| Gross Margin | 32.64% |
| Net Profit Margin | -172.51% |
| Debt/Equity Ratio | 0% |
How did ISPC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/17 23:11 |
| End of Day Share Price | 2025/10/17 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
iSpecimen Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| Constantine Davides | D. Boral Capital LLC. |
| Ashok Kumar | ThinkEquity LLC |